Team Gleason and Synchron, an endovascular brain computer interface company, announce a partnership agreement to provide patient-focused feedback on their platform to transform daily life for patients with physical and speech disabilities caused by conditions like ALS, muscular dystrophy, and cerebral palsy.

The partnership will enable Synchron to collaborate with Team Gleason’s expert committees and an international network of innovators and influencers. Through their community of ALS patients, caregivers, clinicians and technology specialists, Team Gleason will provide Synchron access to user research, including feedback on the Stentrode System’s current overall design for patients and caregivers.

“We’re excited to announce our partnership with Team Gleason, who will assist our team in increasing awareness of endovascular BCI technology that does not require open brain surgery,” says Tom Oxley, MD, CEO & Founder, Synchron. “Our recent results presented at the American Academy of Neurology Conference 2022 show that our permanent BCI implant is safe, and can improve independence and quality of life for those living with ALS.”

“We need more accessible solutions developed and funded for those living with ALS,” says Blair Casey, Team Gleason’s executive director. “Assistive technology empowers those living with limited physical and speech capabilities by improving quality of life and restoring independence. It is imperative to put the patients’ needs first to ensure the technology is inspired by and tested by the community it is intended to serve. This ‘community-first’ architecture will result in a successful user interface to serve not only the ALS population, but everyone who can benefit from emerging technologies like the Stentrode.”

Synchron’s flagship technology, the Stentrode, is an endovascular brain implant designed to enable patients to wirelessly control digital devices through thought and improve functional independence. Synchron’s foundational technology, a motor neuroprosthesis (MNP), is implanted via the jugular vein using neurointerventional techniques commonly used to treat strokes, and does not require drilling into the skull nor does it require open brain surgery. The system is designed for patients suffering from paralysis as a result of a broad range of conditions, and aims to be user friendly and dependable for patients to use autonomously.

[Source(s): Synchron, Business Wire]